Literature DB >> 20665394

Cutaneous sarcoidosis.

Richard M Marchell1, Marc A Judson.   

Abstract

Sarcoidosis is a systemic disease with skin manifestations. Skin manifestations are classified as nonspecific if they are not characterized by granulomatous inflammation and specific if the lesions have granulomas histologically. Erythema nodosum is the most common nonspecific skin manifestation, and it portends a good prognosis. Specific skin lesions have a varied clinical appearance, although often they can be distinguished by their yellow translucent character. Despite the potential variable appearance, there are common clinical presentations. Lupus pernio lesions are nodular violaceous specific skin lesions found predominantly on the face associated with scarring and a poor prognosis. Treatment of cutaneous sarcoidosis is primarily done to avoid scarring and cosmetic disfigurement. Local and systemic corticosteroids are the mainstay of treatment for the disease. Corticosteroid-sparing agents used to manage the disease include antimalarials, methotrexate, and tetracycline antibiotics. Tumor necrosis factor-alpha (TNF-alpha) antagonists such as infliximab may have a role in cutaneous sarcoidosis, especially in refractory cases that are resistant to the standard regimens. Copyright Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20665394     DOI: 10.1055/s-0030-1262212

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  18 in total

Review 1.  Dermatological and immunological conditions due to nerve lesions.

Authors:  D Bove; A Lupoli; S Caccavale; V Piccolo; E Ruocco
Journal:  Funct Neurol       Date:  2013 Apr-May

2.  Pathology of the ear.

Authors:  Ida Orengo; Kerri Robbins; Amanda Marsch
Journal:  Semin Plast Surg       Date:  2011-11       Impact factor: 2.314

3.  Epidemiology of cutaneous sarcoidosis, 1976-2013: a population-based study from Olmsted County, Minnesota.

Authors:  P Ungprasert; D A Wetter; C S Crowson; E L Matteson
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-06-21       Impact factor: 6.166

4.  [Cutaneous and pulmonary sarcoidosis. Successful therapy with fumaric acid esters].

Authors:  A Wolter; M Müller; B Völker; M Gehring; F Caldarone; A Kapp; T Werfel; U Raap
Journal:  Hautarzt       Date:  2012-10       Impact factor: 0.751

5.  Orbital sarcoidosis presenting as diffuse swelling of the lower eyelid.

Authors:  Jeong Kyu Lee; Nam Ju Moon
Journal:  Korean J Ophthalmol       Date:  2013-01-15

6.  Comparison of cutaneous sarcoidosis with systemic sarcoidosis: a retrospective analysis.

Authors:  Chunguang Tong; Xiuying Zhang; Jie Dong; Yanling He
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

7.  Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study.

Authors:  Wonder P Drake; Kyra Oswald-Richter; Bradley W Richmond; Joan Isom; Victoria E Burke; Holly Algood; Nicole Braun; Thyneice Taylor; Kusum V Pandit; Caroline Aboud; Chang Yu; Naftali Kaminski; Alan S Boyd; Lloyd E King
Journal:  JAMA Dermatol       Date:  2013-09       Impact factor: 10.282

8.  Cutaneous manifestations of sarcoidosis.

Authors:  Alka Dogra; Sukhjot Kaur
Journal:  Indian J Dermatol       Date:  2012-05       Impact factor: 1.494

9.  Isolated facial cutaneous sarcoidosis.

Authors:  Sumir Kumar; Ravinder Garg; Simmi Aggarwal; Jaskanwal Kaur
Journal:  J Nat Sci Biol Med       Date:  2012-01

Review 10.  Current and emerging pharmacological treatments for sarcoidosis: a review.

Authors:  Scott H Beegle; Kerry Barba; Romel Gobunsuy; Marc A Judson
Journal:  Drug Des Devel Ther       Date:  2013-04-12       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.